
Neoadjuvant nivolumab plus relatlimab shows benefit in MMR-deficient colon cancers
In the NICHE-3 study, all patients achieved a pathological response
In the NICHE-3 study, all patients achieved a pathological response
Collaboration is needed to advocate for resilient healthcare systems that can navigate crises and deliver high-quality care to patients with cancer, even in the most trying circumstances
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types
Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease
Progression-free survival was longer with tumour-specific versus standard chemotherapy in two trials, but further work is needed to improve prognosis for these patients
Study findings support routine RET-mutation testing for all patients with advanced MTC, but further work is needed to identify predictive markers
Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.